Meeting
2020 Genitourinary Cancers Symposium
Optimal sequence strategy with nivolumab and targeted therapy in patients with metastatic renal cell carcinoma (mRCC).
Authors
Juliette Logeart
Hôpital Européen Georges-Pompidou, Paris, France
Juliette Logeart , Audrey Simonaggio , Reza Thierry Elaidi , Sophie Hans , Constance Thibault , Stephane Oudard , Yann-Alexandre Vano
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer
Track
Renal Cell Cancer
Sub Track
Therapeutics
Citation
J Clin Oncol 38, 2020 (suppl 6; abstr 700)
Abstract #
700
Poster Bd #
G20
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Genitourinary Cancers Symposium
Real-world assessment of changing treatment patterns and sequence for patients with metastatic renal cell carcinoma (mRCC) in the first-line (1L) setting.
First Author: Neil J. Shah
Poster
2024 ASCO Genitourinary Cancers Symposium
Real-world metastatic renal cell carcinoma (mRCC) treatment trends in Mexico: A public vs private sector analysis.
First Author: Iván Romarico González Espinoza
Poster
2021 Genitourinary Cancers Symposium
Treatment sequence after first-line nivolumab plus ipilimumab or sunitinib monotherapy in patients with metastatic renal cell carcinoma (mRCC) using real-world data.
First Author: Daniel M. Geynisman
Poster
2021 Genitourinary Cancers Symposium
The impact of hypertension on response rates in patients with renal cell carcinoma.
First Author: Diana Maslov